Thorir D. Bjornsson - Concepedia

Author

Thorir D. Bjornsson

Also Known As

T D Bjornsson, THORIR D. BJORNSSON, Thorir Bjornsson, Thorir Björnsson, Thorir D Bjornsson, Thorir D. Bjornsson, Thorir D. Bjornsson

Publications

4.8K

Citations

H-Index

114

Concepts

All Affiliations

Duke Medical Center Thomas Jefferson University Duke University Hospital Duke University United States Military Academy

About

Thorir D. Bjornsson is an author at Duke Medical Center specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	21	38	2.1K
2	Engineering	3	3	130
3	Health Sciences	3	3	182
4	Natural Sciences	1	1	15
5	Public Health	1	1	24

Thorir D. Bjornsson

Publications

4.1K

Citations

H-Index

Page 1

	Year	Citations
THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf, Drug Metabolism and Disposition	2003	781
The Conduct of In Vitro and In Vivo Drug‐Drug Interaction Studies: A PhRMA Perspective Thorir D. Bjornsson, John T. Callaghan, Heidi J. Einolf, The Journal of Clinical Pharmacology Drug InteractionsPreclinical Drug EvaluationBiochemistryPharmacological StudyMedicine	2003	309
Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans Man‐Wai Lo, Michael R. Goldberg, Jacqueline B. McCrea, Clinical Pharmacology & Therapeutics	1995	275
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance Barbara J. Ring, Jenny Y. Chien, Kimberly K. Adkison, Journal of Pharmaceutical Sciences Pharmacokinetic ModelingMedicineDrug DiscoveryPrediction MethodsPhrma Cpcdc Initiative	2011	198
Interpatient variability in bioavailability is related to the extent of absorption: Implications for bioavailability and bioequivalence studies Edward T. Hellriegel, Thorir D. Bjornsson, Walter W. Hauck Clinical Pharmacology & Therapeutics NutritionPharmacotherapyPharmacodynamic ModelingPre-clinical PharmacologyMolecular Pharmacology	1996	178
PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach Patrick Poulin, Rhys D.O. Jones, Hannah M. Jones, Journal of Pharmaceutical Sciences Precision DosingPhysiologically Based PharmacokineticsPharmacokinetic ModelingHuman PharmacokineticsMedicine	2011	170
Enhanced clearance of Aβ in brain by sustaining the plasmin proteolysis cascade J. Steven Jacobsen, Thomas A. Comery, Robert Martone, Proceedings of the National Academy of Sciences Neurochemical BiomarkersSocial SciencesEnhanced ClearanceNeuroinflammationAlzheimer's Disease	2008	136
PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: Comparative assessment of prediction methods of human volume of distribution Rhys D.O. Jones, Hannah M. Jones, Malcolm Rowland, Journal of Pharmaceutical Sciences Translational MedicinePharmacokinetic ModelingPart 2Prediction MethodsMedicine	2011	133
Heparin kinetics determined by three assay methods Thorir D. Bjornsson, Katherine M. Wolfram, Barbara B. Kitchell Clinical Pharmacology & Therapeutics	1982	132
Biochemical Effects of Losartan, a Nonpeptide Angiotensin II Receptor Antagonist, on the Renin-Angiotensin-Aldosterone System in Hypertensive Patients Michael R. Goldberg, Thomas E. Bradstreet, Edward J. McWilliams, Hypertension	1995	130

Page 1